Amid recent broader vaccine manufacturing initiatives from the EU and European companies, the G7 summit in the mountains of Bavaria brought some positive news for bridging gaps in vaccine and medical device manufacturing around the world.
G7 leaders have officially launched the Global Infrastructure Partnership, PGII, according to a White House statement. The effort aims to mobilize hundreds of billions of dollars to implement infrastructure projects across multiple sectors, including medical and pharmaceutical manufacturing.
The US will seek to mobilize $200 billion for PGII over the next five years through grants, federal funding and private sector investment. Together with the other G7 countries, a total of 600 billion US dollars will be mobilized for a large number of global infrastructure investments by 2027.
One of the first projects includes G7 members, the EU, multilateral organizations and the US International Development Finance Corporation (DFC), which has awarded a US$3.3 million technical assistance grant to the Institut Pasteur de Pay off Dakar (IPD) in Senegal.
The funds will be used to develop a flexible industrial-scale production facility for multiple vaccines. The facility will have the potential to produce millions of doses of vaccines for Covid-19 and other diseases, with the potential to use both viral vector and mRNA technologies.
This comes at a time when Africa is increasingly becoming the focus of vaccine production.
On Thursday, BioNTech started construction work on an mRNA production facility in Kigali, Rwanda. According to BioNTech, the facility — which will be dubbed the African modular mRNA manufacturing facility — has a goal of delivering the first set of manufacturing tooling to the site by the end of this year.
The Serum Institute also said in May it was considering establishing its first manufacturing facility in Africa as part of another step toward global expansion, after successfully mass-producing and selling hundreds of millions of Covid-19 vaccine doses from its India-based facilities .
It also follows the EU launching a new vaccine and drug manufacturing initiative in Latin America and the Caribbean to get medicines to the region faster.